MarketPulse

FDA submissions

1 articles
The Motley FoolThe Motley Fool··Motley Fool Transcribing

OraSure Charts Path to Profitability With Margin Expansion and FDA Pipeline

OraSure posts 4% Q1 revenue growth to $27.9M with gross margin expansion to 42.3%, maintaining $177M cash. Two FDA submissions expected midyear clearance with 2027 breakeven guidance.
OSURoperating lossescash position